Navigation Links
Olympus Unveils New Dissolvable Post Sinus Surgery Products
Date:1/5/2012

CENTER VALLEY, Pa., Jan. 5, 2012 /PRNewswire/ -- Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, today announced the addition of a broad line of advanced, dissolvable sinus spacing and hemostat products to its already extensive ENT product portfolio. These products include spacers, foams and powders available in either plant-based or chitosan polysaccharide polymers.

Through a distribution partnership with Hemostasis, LLC, the plant-based and chitosan compositions have been formulated to improve post sinus surgery recovery, comfort and healing. All products are biocompatible, dissolve naturally, require no mixing or special storage considerations and are easily conformed to fit nasal anatomy. Additionally, the sinus products minimize edema, bleeding and prevent post operative adhesions by maintaining space between the upper chambers of the nasal cavities.  

"The new offerings extend Olympus' current world-class ENT solutions to surgeons performing sinus and anterior skull base procedures and their patients," commented Perry Mykleby, Vice President of Marketing for Olympus' ENT sales. "We are pleased to collaborate with Hemostasis, a high-quality medical device manufacturer partner, to enhance patient care."

"Hemostasis is committed to providing the most comprehensive, technologically advanced ENT sinus spacing and hemostat technologies that are safe and effective for their intended use," said Hemostasis' President, Keith Roberts. "Working directly with leading physicians, we have developed practical technologies designed to optimize physician usability and efficacy, which ultimately have improved procedure outcomes and enhances overall patient care."

About Olympus Medical Systems ENT Business
Olympus develops procedure solutions for healthcare professionals that help improve outcomes and enhance quality of life for their patients. Our ENT Business offers advanced visualization and treatment products for Rhinology, Pediatric ENT, Laryngology, Otology, Sleep and Head and Neck procedures. Products include endoscopy and video; powered electrosurgical and manual instruments, middle ear prosthetics, and vent (PE) tubes.

For more information about Olympus America, visit www.olympusamerica.com.
For more information about ENT products, click here.

About Hemostasis, LLC
Hemostasis is a dynamic company committed to developing and marketing innovative technologies for the rapidly changing demands of the global medical industry. We work directly with leading physicians to develop practical products that are designed to optimize usability and efficacy for medical professionals, improve procedure outcomes and enhance overall patient care. www.hemostasisllc.com.


'/>"/>
SOURCE Olympus America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omnyx Licenses Olympus Digital Pathology Patents
2. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
3. Olympus Launches 2011 National Innovation Awards Program
4. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
5. Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus
6. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
7. Olympus Biotech Names Oliver Burckhardt to President North America
8. Olympus Introduces Worlds First Autoclavable 5mm HD Deflectable Videolaparoscope
9. Olympus Introduces New Peracetic Acid Solution for Rapid High-Level Disinfection
10. Olympus Broadens Portfolio With a Suite of New Single-Use Aspiration Needles
11. Oregon Tourism Commission Unveils New Online Customer Service Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology:
(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... the acquisition of Isle at Kingwood Assisted Living and Memory Care located at ... retirement community with 55 assisted living apartments, 43 memory care apartments and 23 ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
Breaking Medicine News(10 mins):